Roche and Bristol Myers Squibb have collaborated to develop and deploy two assays with new digital pathology algorithms for use in clinical trials.

Under the collaboration, Roche Digital Pathology is developing an artificial intelligence (AI)-based image analysis algorithm in the first project.

The algorithm will help pathologists interpret the VENTANA PD-L1 (SP142) Assay.

It will be used by Bristol Myers Squibb to generate biomarker data from clinical trial samples.

Roche will use its recently announced Open Environment collaboration with PathAI in the second project to integrate an algorithm developed by the latter into its NAVIFY Digital Pathology workflow software for the CD8 biomarker analysis.

Bristol Myers will use the AI-powered algorithm to analyse clinical trial samples stained with Roche’s CD8 assay and produce quantitative spatial biomarker data.

The companies will use the data generated from the two projects to support cancer diagnosis and advance personalised healthcare treatment options.

Roche Diagnostics pathology customer area head Jill German said: “The Bristol Myers Squibb and PathAI collaborations are among the first examples where AI technology and digital pathology applications are playing a role in developing treatments for patients.

“By using our NAVIFY Digital platform to interpret tissue-based assays and AI algorithms, pathologists are better able to identify targeted therapy options, ultimately improving patient care.”

The company stated that the AI-based pathology imaging tools will support clinical trials in the study of targeted therapy options.

Additionally, expanding access to these tools is expected to deliver improved clinical decision-making, precise diagnoses and more personalised treatment strategies.